加科思-B(01167.HK)公布，自主研發的KRAS G12C抑制劑產品Glecirasib(JAB-21822)新藥上市申請，已獲得中國國家藥監局正式受理，並納入優先審評程序，用於治療二線及以上治療帶有KRAS G12C突變的晚期或轉移性非小細胞肺癌患者。
加科思(01167.HK)抑制劑新藥內地上市申請獲受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.